David E. Gilham

Manchester Cancer Research Centre Building, University of Manchester

Affiliated withUniversity of Manchester Celyad

Research Area

Biography

David E. Gilham has not added Biography.
If you are David E. Gilham and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 16	2018

Other Publications

Article	Year
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 12074044	2002
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Diseases of the colon and rectum\| PubMed ID: 12794582	2003
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 15838376	2005
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. British journal of haematology\| PubMed ID: 15842655	2005
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 16982863	2006
Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK. Cancer immunology, immunotherapy : CII\| PubMed ID: 17333180	2007
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer immunology, immunotherapy : CII\| PubMed ID: 17899077	2008
Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17908961	2007
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. British medical bulletin\| PubMed ID: 18245773	2008
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. British journal of haematology\| PubMed ID: 18477047	2008
The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy. Cancer immunology, immunotherapy : CII\| PubMed ID: 19669146	2010
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. The journal of gene medicine\| PubMed ID: 20033928	2010
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry. Part A : the journal of the International Society for Analytical Cytology\| PubMed ID: 20033991	2010
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 20089697	2010
Development of adoptive cell therapy for cancer: a clinical perspective. Human gene therapy\| PubMed ID: 20408760	2010
Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. Human gene therapy\| PubMed ID: 20528679	2010
Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 20736928	2010
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer immunology, immunotherapy : CII\| PubMed ID: 22127365	2012
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer immunology, immunotherapy : CII\| PubMed ID: 22527245	2012
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends in molecular medicine\| PubMed ID: 22613370	2012
Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? Breast cancer research : BCR\| PubMed ID: 22643384	2012
Chimeric antigen receptors for T-cell based therapy. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 22907378	2012
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Human gene therapy methods\| PubMed ID: 23931270	2013
Targeting T cells to tumor: exploiting the chimeric antibody receptor. Immunotherapy\| PubMed ID: 23998728	2013
Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol. Human gene therapy methods\| PubMed ID: 24028672	2013
CAR T cells: driving the road from the laboratory to the clinic. Immunological reviews\| PubMed ID: 24329792	2014
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 24623129	2014
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity... Cancer immunology, immunotherapy : CII\| PubMed ID: 28660319	2017
Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 29239915	2018
Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. Cancer immunology, immunotherapy : CII\| PubMed ID: 30039427	2018